2-[2,5-difluoro-4-[(5-isoquinolin-1-yltetrazol-2-yl)methyl]phenyl]-5-(difluoromethyl)-1,3,4-oxadiazole
C20H11F4N7O — CID 162722195
Data last refreshed: (MolForge compound catalog, from PubChem)
About 2-[2,5-difluoro-4-[(5-isoquinolin-1-yltetrazol-2-yl)methyl]phenyl]-5-(difluoromethyl)-1,3,4-oxadiazole
2-[2,5-difluoro-4-[(5-isoquinolin-1-yltetrazol-2-yl)methyl]phenyl]-5-(difluoromethyl)-1,3,4-oxadiazole (PubChem CID 162722195) has the molecular formula C20H11F4N7O and a molecular weight of 441.35 g/mol. Its IUPAC name is 2-[2,5-difluoro-4-[(5-isoquinolin-1-yltetrazol-2-yl)methyl]phenyl]-5-(difluoromethyl)-1,3,4-oxadiazole.
Molecular Properties
| Compound Name | 2-[2,5-difluoro-4-[(5-isoquinolin-1-yltetrazol-2-yl)methyl]phenyl]-5-(difluoromethyl)-1,3,4-oxadiazole |
|---|---|
| PubChem CID | 162722195 |
| Molecular Formula | C20H11F4N7O |
| Molecular Weight | 441.35 g/mol |
| Exact Mass | 441.10 |
| IUPAC Name | 2-[2,5-difluoro-4-[(5-isoquinolin-1-yltetrazol-2-yl)methyl]phenyl]-5-(difluoromethyl)-1,3,4-oxadiazole |
| SMILES | Fc1cc(-c2nnc(C(F)F)o2)c(F)cc1Cn1nnc(-c2nccc3ccccc23)n1 |
| InChI | InChI=1S/C20H11F4N7O/c21-14-8-13(19-27-28-20(32-19)17(23)24)15(22)7-11(14)9-31-29-18(26-30-31)16-12-4-2-1-3-10(12)5-6-25-16/h1-8,17H,9H2 |
| InChIKey | ZGSKHAOWMLDXMP-UHFFFAOYSA-N |
| XLogP | 4.20 |
| TPSA | 95.41 Ų |
| H-Bond Donors | |
| H-Bond Acceptors | 8 |
| Rotatable Bonds | 5 |
| Heavy Atoms | 32 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 441.35 |
| LogP ≤ 5 | 4.20 |
| H-Bond Donors ≤ 5 | 0 |
| H-Bond Acceptors ≤ 10 | 8 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 162722195 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.